BioPharma Dive ٢٩ مايو ٢٠٢٦ Replimune takes third swing at cancer drug approval following ‘productive’ FDA talks
BioPharma Dive ٢٦ مايو ٢٠٢٦ SR One’s Simeon George on how China is rewriting biotech’s venture playbook